Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04406389 · ClinicalTrials.gov registry record · Phase 4
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT04406389 is a Phase 4 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 14 participants.
The verdict
NCT04406389, a Phase 4 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis (control group). Following screening, subjects will be randomized 1:1 to intermediate dose prophylaxis or therapeutic dose anticoagulation treatment arms.Treatment will continue for 28 days, followed by a 6 month follow-up period.
Interventions
- DRUG Argatroban
- DRUG Enoxaparin sodium
- DRUG Unfractionated heparin
- DRUG Fondapariniux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2022-04-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04406389
The ClinicalTrials.gov registry entry for NCT04406389 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Argatroban is the first listed.
NCT04406389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04406389 about?
NCT04406389 is a clinical study titled "Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)". The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis (control group). Following screening, subjects will be randomized 1:1 to i...
What is the current status of trial NCT04406389?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2020-10-13. Estimated completion is 2022-04-21.
What interventions are being tested in trial NCT04406389?
The interventions under investigation include: Argatroban (DRUG), Enoxaparin sodium (DRUG), Unfractionated heparin (DRUG), Fondapariniux (DRUG).
Who is sponsoring clinical trial NCT04406389?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.